Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease
説明
<jats:title>Abstract</jats:title><jats:p>It has previously been shown that the consumption of probiotics may have beneficial effects not only on peripheral tissues but also on the central nervous system and behavior via the microbiota–gut–brain axis, raising the possibility that treatment with probiotics could be an effective therapeutic strategy for managing neurodegenerative disorders. In this study, we investigated the effects of oral administration of<jats:italic>Bifidobacterium breve</jats:italic>strain A1 (<jats:italic>B. breve</jats:italic>A1) on behavior and physiological processes in Alzheimer’s disease (AD) model mice. We found that administration of<jats:italic>B. breve</jats:italic>A1 to AD mice reversed the impairment of alternation behavior in a Y maze test and the reduced latency time in a passive avoidance test, indicating that it prevented cognitive dysfunction. We also demonstrated that non-viable components of the bacterium or its metabolite acetate partially ameliorated the cognitive decline observed in AD mice. Gene profiling analysis revealed that the consumption of<jats:italic>B. breve</jats:italic>A1 suppressed the hippocampal expressions of inflammation and immune-reactive genes that are induced by amyloid-β. Together, these findings suggest that<jats:italic>B. breve</jats:italic>A1 has therapeutic potential for preventing cognitive impairment in AD.</jats:p>
収録刊行物
-
- Scientific Reports
-
Scientific Reports 7 (1), 13510-, 2017-10-18
Springer Science and Business Media LLC
